Conference Correspondent

ESMO 2020





Adding abemaciclib to endocrine therapy led to a significant reduction in invasive disease recurrence versus endocrine therapy alone in HR-positive, HER2-negative early-stage breast cancer, according to the results of a new study. “This is a very important trial, and the findings will change practice,” said Giuseppe Curigliano, MD, PhD. Read More ›

For patients with recurrent ovarian cancer progressing within 6 to 12 months after their last platinum line, a combination of trabectedin and pegylated liposomal doxorubicin (PLD) did not demonstrate superiority over a combination of carboplatin and PLD. Read More ›

XMT-1536 is an antibody-drug conjugate that targets the sodium-phosphate cotransporter NaPi2b, which is commonly expressed in solid tumors such as high-grade serous ovarian cancer. Treatment with XMT-1536 results in an overall response rate of 34% in patients with advanced disease; antitumor activity is positively correlated with a higher NaPi2b expression. Read More ›

Results from the PAOLA/ENGOT-ov25 study indicate that adding olaparib to maintenance bevacizumab after first-line platinum-based chemotherapy for patients with newly diagnosed high-grade ovarian cancer improves second progression-free survival and time to second subsequent therapy or death. Read More ›

Platinum treatment after PARP inhibitor failure in patients with high-grade serous ovarian cancer was most effective in terms of objective response rate, progression-free survival, and overall survival when the platinum-free interval was >12 months Read More ›

Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab as first-line treatment for patients with newly diagnosed stage III or stage IV ovarian cancer did not improve progression-free survival or overall survival but exploratory subgroup analyses are ongoing. Read More ›

Page 1 of 3


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: